- The Wall Street Journal•3 hours ago
The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products.
- The Wall Street Journal•23 hours ago
Irish drugmaker Mallinckrodt and a U.S. subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for Acthar, a drug ...
- Motley Fool•yesterday
MannKind plans to more than double its sales force and air TV commercials plus more to increase Afrezza sales. Will this plan work?
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||75.38 - 76.69|
|52 Week Range||62.50 - 79.07|
|PE Ratio (TTM)||23.25|
|Dividend & Yield||3.35 (4.05%)|
|1y Target Est||N/A|